Crossmark

Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi

Crossref DOI link: https://doi.org/10.1007/s13300-019-0569-7

Published Online: 2019-01-31

Published Print: 2019-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pöhlmann, Johannes https://orcid.org/0000-0002-8065-755X
Russel-Szymczyk, Monika

Holík, Pavel

Rychna, Karel

Hunt, Barnaby https://orcid.org/0000-0001-5420-279X
Funding

Funding for this research was provided by:

Novo Nordisk
License Information

Text and Data Mining valid from 2019-01-31

Version of Record valid from 2019-01-31
More Information

Article History

Received: 11 December 2018

First Online: 31 January 2019